After Moderna Inc. lowered its revenue expectations earlier this month, the company’s swollen stock price plunged over the next two weeks by more than 32%, signifying that BioWorld’s Drug Developers Index can no longer rely solely on one company to keep industry stocks in positive territory.
A busy regulatory environment globally throughout most of 2021 has translated into more than 15% of all actions taken relating to the COVID-19 pandemic, yet only one product has been approved in the U.S. for the SARS-CoV-2 virus.
Continuing its downward trend, BioWorld’s Cancer Index (BCI) has fallen by 19.16% this year, a stark contrast with the broader Nasdaq Biopharmaceutical Index and the Dow Jones Industrial Average, both of which are tracking up by 4.49% and 19.03%, respectively.
A surge in deal activity over the last few months has placed 2021 in the running for beating 2020, the best year on record, and becoming the top year for the biopharma industry to date.
BioWorld has recorded 1,680 deals valued at $167.39 billion in 2021 vs. 1,744 deals valued at $159.98 billion by this point last year. That puts 2021 ahead by about 5% on deal values.
RSS
